Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

Rhea-AI Summary

Odyssey Health, Inc. (OTC: ODYY) has filed for patent protection for its innovative intranasal brain-drug delivery device, designed to treat concussions. The recently completed Phase I study confirmed the safety and effectiveness of using this device with Odyssey's concussion drug, PRV-002, on 40 healthy volunteers. The study observed no device failures, indicating strong performance. This technology aims to enhance drug delivery for central nervous system conditions, potentially leading to significant market opportunities in the healthcare sector.

Positive

• Successful Phase I study showed safety of PRV-002 with the Nasal Device.
• Nasal Device demonstrated no failures during clinical trials.
• Innovative delivery system could provide quicker drug absorption and reduced side effects.

Negative

• None.

Las Vegas, Nevada, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc. (the "Company" or "Odyssey"), announces that it has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As announced, Odyssey’s recently completed Phase I study to treat concussion successfully used Odyssey’s Nasal Device and drug combination.

Odyssey designed the Nasal Device with a novel drug dispensing system that creates an effective airflow for depositing concentrated drug deep into the nasal cavity and onto the olfactory region for quick and direct diffusion into the brain to treat central nervous system (“CNS”) injury, disease or disorder.

The Phase I study used Odyssey’s novel Nasal Device to deliver Odyssey’s concussion drug, PRV-002, and to determine the safety of its PRV-002 concussion drug. The PRV-002 concussion drug-Nasal Device combination was well-tolerated in forty (40) healthy human volunteers.  The study documented no Nasal Device failures.

“We were very pleased with the functionality and performance of the Nasal Device during the Phase I study and its administration of Odyssey’s PRV-002 concussion drug. The ability to get drugs for neurological conditions delivered directly into the brain rapidly at effective levels while simultaneously having less concern for side effects is a huge advantage in the development of safe and efficacious treatments. Odyssey’s novel Nasal device provides that opportunity and advantage,” commented Michael Redmond, CEO of Odyssey.

About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in life-saving medical products and solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com

We encourage our shareholders to visit our corporate social media accounts for updates:
https://twitter.com/OdysseyHealth1
https://www.facebook.com/odysseyhealthinc
https://www.linkedin.com/company/odysseyhealthinc
https://www.youtube.com/channel/UCsS--v0od_fYIBu2tvqmj9Q

About PRV-002
PRV-002 is a synthetic non-naturally occurring neurosteroid being developed to treat central nervous system (“CNS”) injury, disease or disorder, such as, traumatic brain injury (“TBI”), especially mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance.  Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.

Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the Phase I trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.

Inquiries:
Odyssey Health
info@odysseyhealthinc.com

FAQ

What is Odyssey Health, Inc.'s recent patent filing about ODYY?

Odyssey Health has filed for patent protection for its intranasal brain-drug delivery device aimed at treating concussions.

What were the results of the Phase I study for ODYY?

The Phase I study confirmed that the Nasal Device and PRV-002 drug combination was safe and well-tolerated in 40 healthy volunteers.

How does the Nasal Device work for ODYY?

The Nasal Device uses a unique drug dispensing system to deliver drugs quickly into the nasal cavity for efficient absorption into the brain.

What is PRV-002 being developed for by ODYY?

PRV-002 is being developed to treat central nervous system injuries and disorders, particularly concussions.

Is there any risk mentioned in the press release for ODYY?

The forward-looking statements caution about uncertainties in funding, product development, and market demand.